These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

826 related articles for article (PubMed ID: 12941844)

  • 1. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
    Nimmanapalli R; Fuino L; Bali P; Gasparetto M; Glozak M; Tao J; Moscinski L; Smith C; Wu J; Jove R; Atadja P; Bhalla K
    Cancer Res; 2003 Aug; 63(16):5126-35. PubMed ID: 12941844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
    George P; Bali P; Annavarapu S; Scuto A; Fiskus W; Guo F; Sigua C; Sondarva G; Moscinski L; Atadja P; Bhalla K
    Blood; 2005 Feb; 105(4):1768-76. PubMed ID: 15514006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
    Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
    Nimmanapalli R; Fuino L; Stobaugh C; Richon V; Bhalla K
    Blood; 2003 Apr; 101(8):3236-9. PubMed ID: 12446442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
    Yu C; Rahmani M; Almenara J; Subler M; Krystal G; Conrad D; Varticovski L; Dent P; Grant S
    Cancer Res; 2003 May; 63(9):2118-26. PubMed ID: 12727828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M; Nguyen TK; Dent P; Grant S
    Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
    Okabe S; Tauchi T; Nakajima A; Sashida G; Gotoh A; Broxmeyer HE; Ohyashiki JH; Ohyashiki K
    Stem Cells Dev; 2007 Jun; 16(3):503-14. PubMed ID: 17610380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors.
    Brieger A; Boehrer S; Schaaf S; Nowak D; Ruthardt M; Kim SZ; Atadja P; Hoelzer D; Mitrou PS; Weidmann E; Chow KU
    Biochem Pharmacol; 2004 Jul; 68(1):85-93. PubMed ID: 15183120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors.
    Lee SM; Bae JH; Kim MJ; Lee HS; Lee MK; Chung BS; Kim DW; Kang CD; Kim SH
    J Pharmacol Exp Ther; 2007 Sep; 322(3):1084-92. PubMed ID: 17569822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo.
    Weisberg E; Catley L; Kujawa J; Atadja P; Remiszewski S; Fuerst P; Cavazza C; Anderson K; Griffin JD
    Leukemia; 2004 Dec; 18(12):1951-63. PubMed ID: 15496979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
    Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
    Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
    Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells.
    Cheong JW; Chong SY; Kim JY; Eom JI; Jeung HK; Maeng HY; Lee ST; Min YH
    Clin Cancer Res; 2003 Oct; 9(13):5018-27. PubMed ID: 14581377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
    Andreu EJ; Lledó E; Poch E; Ivorra C; Albero MP; Martínez-Climent JA; Montiel-Duarte C; Rifón J; Pérez-Calvo J; Arbona C; Prósper F; Pérez-Roger I
    Cancer Res; 2005 Apr; 65(8):3264-72. PubMed ID: 15833859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines.
    Xu Y; Voelter-Mahlknecht S; Mahlknecht U
    Int J Mol Med; 2005 Jan; 15(1):169-72. PubMed ID: 15583844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
    Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
    Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.